Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-31

Study Completion Date

2025-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if stimulation of the vagus nerve via a non-invasive device placed behind external ear can reduce physical and psychological discomfort during acute alcohol withdrawal in patients with alcohol use disorder when people just stop drinking alcohol and in detoxification stage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of tAN® in Alcohol Withdrawal Management

NCT06771037

Alcohol Withdrawal

RECRUITING NA

Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder

NCT06399653

Alcohol Use Disorder

RECRUITING NA

Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder

NCT05226130

Alcohol Use Disorder

COMPLETED PHASE1

Pilot Evaluation of the Empower Neuromodulation System in AUD Patients

NCT03983317

Alcohol Use Disorder

COMPLETED NA

Oxytocin Treatment of Alcohol Dependence

NCT02275611

Alcohol Withdrawal Alcohol Dependence

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The management of acute alcohol withdrawal is a clinical challenge, in part because there are limited medications available for the condition and the majority of the medications are controlled substances, which may cause significant adverse effects and can be potentially addictive.

The rationale for using transcutaneous auricular VNS (taVNS) on a specific target area of the ear is based on anatomical studies suggesting that this area is the only place on the human body surface where there is afferent vagus nerve distribution (Mercante et al., 2018). Therefore, direct stimulation of the afferent nerve fibers on the ear can produce an effect similar to that by implanted device-generated VNS yet without the need of surgical intervention. Although taVNS has not been tested for treatment of AUD, it interestingly appears to be very similar to auricular acupuncture that has been widely used for AUD. However, acupuncture needs to be administered by medical providers who have undergone long trainings and own special licensure, which is usually unavailable in acute detoxification units where patients receive treatment for acute alcohol withdrawal.

The pilot study will enroll 70 evaluable subjects who are in inpatient detoxification unit randomized to receive single-blind treatment with vagus nerve stimulation or sham stimulation (1:1, VNS: sham). Evaluable subjects are those who complete stimulations (VNS) or sham 5 minutes twice a day for 4 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Withdrawal Alcohol Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, single-blinded Treatment vs sham

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VNS transcutaneous stimulation

5 minutes of stimulation (VNS) twice a day for 4 days. Patients will receive transcutaneous stimulation (30 Hz, 300 msec.) on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days. Due to the theoretical risk that right vagus nerve stimulation could affect the heart, and to ensure consistency of the intervention, all subjects randomized to receive transcutaneous vagus nerve stimulation will receive stimulation of the auricular branch of the left vagus nerve. The subject will be blinded to their treatment arm.

The device to be used will include a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed "Cymba Concha". Electrodes will be placed on this area to provide stimulation to the auricular branch of the afferent vagus nerve.

Group Type EXPERIMENTAL

Transcutaneous Nerve Stimulation

Intervention Type DEVICE

510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days

Sham stimulation

5 minutes of sham stimulation (no electrical stimulation) twice a day for 4 days Patients will receive sham stimulation on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days.

The subject will be blinded to their treatment arm. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed "Cymba Concha". Electrodes will be placed on this area to provide sham stimulation (no electrical current) to the auricular branch of the afferent vagus nerve.

Group Type SHAM_COMPARATOR

Sham Stimulation

Intervention Type DEVICE

sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcutaneous Nerve Stimulation

510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days

Intervention Type DEVICE

Sham Stimulation

sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. age 18-65 years (men and women);
2. primary current diagnosis of DSM-V Alcohol Use Disorder as indicated at admission;
3. being admitted to inpatient detoxification unit;
4. no evidence of significant cognitive impairment with a mini mental state examination (MMSE; Folstein et al., 1975) score \> 22;
5. able and willing to give written informed consent and comply with the requirements of the study protocol.

Exclusion Criteria

1. current DSM-V substance use disorders (other than tobacco / cannabis/ alcohol);
2. serious psychiatric illnesses, e.g. psychotic disorders or bipolar disorder
3. severe medical illnesses, present or history of, e.g. hepatic encephalopathy, delirium
4. history of significant medical problems associated with drinking including seizures;
5. pregnancy;
6. severe intellectual/cognitive deficits due to Korsakoff's syndrome, dementia, head injury, or others
7. treatment with an anti-cholinergic medication, including over the counter medications,
8. implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No